Rare Diseases Today—April 23, 2026

This week’s Rare Diseases update highlights late-stage clinical progress, regulatory momentum, commercial expansion, and partnership activity across autoimmune, hematology, nephrology, oncology, and genetic disorders.

In Today’s Newsletter

Dive deeper

🧬 Kyverna Therapeutics’ miv-cel advances in autoimmune disease [1] [US • 21 Apr 2026]

https://www.fiercebiotech.com/biotech/racing-toward-first-fda-nod-autoimmune-car-t-kyverna-bolsters-lead-full-sps-dataset
Context: In 26 patients, the report cited a 46% mean improvement in timed 25-foot walk at week 16, discontinuation of background immunomodulatory or immunosuppressive therapy in all patients at last follow-up, and manageable safety with low-grade CRS and limited grade 1 ICANS [1].
Key point: Mivocabtagene autoleucel (Kyverna Therapeutics; CD19 CAR-T) showed positive primary, secondary, and exploratory results in the registrational Phase 2 KYSA-8 study in stiff person syndrome, with the company indicating plans to file for full FDA approval [1].
Implication: May influence prescriber choice and payer reviews pending full data.

🏥 Soleo Health launches SoleoRare specialty pharmacy [2] [US • 20 Apr 2026]

https://www.globenewswire.com/news-release/2026/04/20/3276843/0/en/Soleo-Health-Expands-Rare-Disease-Capabilities-With-Launch-of-SoleoRare-A-Specialty-Pharmacy-Focused-on-Complex-Patient-Needs.html
Context: The company positioned the launch as an expansion of existing rare disease capabilities for rare, ultra-rare, and orphan conditions, serving patients, providers, payors, and manufacturer partners [2].
Key point: Soleo Health launched SoleoRare, a dedicated rare disease specialty pharmacy brand that combines patient care, access, and commercial teams under a clinician-led, patient-centered model [2].
Implication: May expand screening, initiation, and follow-up at scale.

🩹 Medicus Pharma seeks orphan status for SkinJect in Gorlin syndrome [3] [US • 17 Apr 2026]

https://medicuspharma.com/medicus-pharma-submits-orphan-drug-designation-application-to-u-s-fda-for-skinject-in-gorlin-syndrome/
Context: The company described SkinJect as a doxorubicin-containing dissolvable microneedle array for localized intradermal delivery and framed the program around a non-surgical, repeatable treatment approach in a setting with no FDA-approved therapies specific to this use [3].
Key point: Medicus Pharma submitted an FDA orphan drug designation application for SkinJect (D-MNA) in basal cell carcinoma associated with Gorlin syndrome [3].
Implication: Introduces competition that may affect pricing and formulary access.

🧪 Orion Pharma wins FDA orphan designation for ODM-212 in mesothelioma [4] [US • 20 Apr 2026]

https://www.globenewswire.com/news-release/2026/04/20/3277035/0/en/Orion-Pharma-s-ODM-212-Granted-Orphan-Drug-Designation-in-Mesothelioma-by-the-US-FDA.html
Context: ODM-212 is an oral pan-TEAD inhibitor in the global Phase 2 TEADES study for malignant pleural mesothelioma, epithelioid hemangioendothelioma, and other solid tumors with Hippo pathway dysfunction; primary endpoints are safety and tolerability [4].
Key point: Orion Pharma said the FDA granted orphan drug designation to ODM-212 for mesothelioma [4].
Implication: Introduces competition that may affect pricing and formulary access.

🧠 Roche’s ENSPRYNG hits Phase III endpoint in MOGAD [5] [21 Apr 2026]

https://www.roche.com/media/releases/med-cor-2026-04-21b
Context: Roche reported 87% of treated patients were relapse-free versus 67% on placebo at 48 weeks, plus significant effects on annualised relapse rate, MRI lesions, and rescue therapy use; no new safety signals were reported [5].
Key point: ENSPRYNG (satralizumab, Roche) met the primary endpoint in the Phase III METEOROID study in MOGAD, reducing risk of relapse by 68% versus placebo [5].
Implication: May influence prescriber choice and payer reviews pending full data.

🩸 Star Therapeutics gains two FDA designations for VGA039 [6] [US • 21 Apr 2026]

https://www.businesswire.com/news/home/20260420175701/en/Star-Therapeutics-Receives-FDA-Rare-Pediatric-Disease-and-Breakthrough-Therapy-Designations-for-VGA039-in-Von-Willebrand-Disease-Prophylaxis
Context: VGA039 is a once-monthly, subcutaneous monoclonal antibody targeting Protein S; a pivotal Phase 3 trial in patients aged 12 years and older is enrolling, and the designation package was supported by interim Phase 1/2 data [6].
Key point: Star Therapeutics said the FDA granted rare pediatric disease and Breakthrough Therapy designations to VGA039 for routine prophylaxis in von Willebrand disease [6].
Implication: Introduces competition that may affect pricing and formulary access.

🧫 Novo Nordisk’s etavopivat posts pivotal Phase 3 sickle cell win [7] [20 Apr 2026]

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916533
Context: In 385 participants aged 12 years or older, etavopivat reduced annualised vaso-occlusive crises by 27% versus placebo and improved haemoglobin response at week 24, with regulatory submission planned in the second half of 2026 [7].
Key point: Etavopivat (Novo Nordisk; PKR activator) met both co-primary endpoints in the Phase 3 HIBISCUS trial in sickle cell disease [7].
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 AstraZeneca’s Ultomiris meets interim Phase III endpoint in IgAN [8] [21 Apr 2026]

https://www.astrazeneca.com/media-centre/press-releases/2026/i-can-phiii-interim-analysis-met-primary-endpoint.html
Context: The company reported a statistically significant and clinically meaningful reduction in proteinuria at week 34, with rapid effect as early as week 10; the eGFR endpoint remains due at week 106, and no new safety concerns were identified [8].
Key point: Ultomiris (ravulizumab, Alexion/AstraZeneca Rare Disease) met the primary endpoint in a prespecified interim analysis of the Phase III I CAN trial in adults with IgA nephropathy at risk of progression [8].
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Entos Pharmaceuticals partners on LMNA-related congenital muscular dystrophy [9] [20 Apr 2026]

https://www.businesswire.com/news/home/20260420276441/en/Entos-Pharmaceuticals-and-the-L-CMD-Research-Foundation-Collaborate-to-Develop-Curative-Therapy-for-LMNA-Related-Congenital-Muscular-Dystrophy
Context: The effort combines Entos’ non-viral, redosable Fusogenix PLV delivery platform with gene-editing approaches and muscle-targeted formulations developed in Duchenne muscular dystrophy work (clinical specifics not stated) [9].
Key point: Entos Pharmaceuticals and the L-CMD Research Foundation entered a collaboration to develop a potentially curative therapy for LMNA-related congenital muscular dystrophy [9].
Implication: Signals pipeline investment and modality expansion.

Why it matters

Autoimmune and neuroimmunology programs led this week’s catalyst flow, with Kyverna in stiff person syndrome and Roche in MOGAD both targeting areas with limited or no approved options [1][5].
Rare disease regulatory momentum remained broad, spanning orphan, Breakthrough Therapy, and rare pediatric disease pathways across oncology, dermatology, and bleeding disorders [3][4][6].
Late-stage readouts in sickle cell disease and IgA nephropathy may shape near-term regulatory filings and commercial positioning in high-burden specialty markets [7][8].
Infrastructure is also moving, not just molecules, as SoleoRare expands specialty pharmacy capacity for rare conditions [2].
Platform plays remain active in ultra-rare disease, with Entos positioning redosable non-viral delivery for future genetic medicine programs [9].

📚 View the full Rare Disease archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Rare Disease news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is miv-cel, and why is Kyverna’s stiff person syndrome dataset notable?

Mivocabtagene autoleucel is a CD19 CAR-T from Kyverna Therapeutics. The company reported registrational Phase 2 results in stiff person syndrome with broad endpoint improvement and said it expects to file for full FDA approval [1].

What did Roche show with ENSPRYNG in MOGAD?

Roche said ENSPRYNG reduced relapse risk by 68% versus placebo in the Phase III METEOROID trial and plans regulatory submissions. The source describes this as a pivotal study in a disease with no approved therapies [5].

How far along is etavopivat in sickle cell disease?

Etavopivat met both co-primary endpoints in the Phase 3 HIBISCUS trial, including lower vaso-occlusive crisis burden and improved haemoglobin response. Novo Nordisk said it plans the first regulatory submission in the second half of 2026 [7].

What does the Ultomiris IgAN update actually show so far?

The AstraZeneca, Alexion update is from a prespecified interim analysis. It shows a statistically significant and clinically meaningful reduction in proteinuria at week 34, while the eGFR endpoint remains scheduled for week 106 [8].

Why do the FDA designations for VGA039 matter?

Star Therapeutics said VGA039 received both rare pediatric disease and Breakthrough Therapy designations in von Willebrand disease prophylaxis. These can support expedited development and, if approved, rare pediatric disease designation may make the program eligible for a priority review voucher [6].

Is SoleoRare a drug launch?

No. SoleoRare is a specialty pharmacy brand from Soleo Health focused on rare disease services, patient access, and commercial support rather than a therapeutic product [2].

Entities / Keywords

Kyverna Therapeutics: mivocabtagene autoleucel, miv-cel, CD19 CAR-T, stiff person syndrome, SPS, KYSA-8, generalized myasthenia gravis, gMG, KYSA-6
Soleo Health: SoleoRare, rare disease specialty pharmacy, patient access, specialty pharmacy services
Medicus Pharma: SkinJect, D-MNA, Gorlin syndrome, nevoid basal cell carcinoma syndrome, basal cell carcinoma, BCC, orphan drug designation
Orion Pharma: ODM-212, pan-TEAD inhibitor, mesothelioma, malignant pleural mesothelioma, MPM, TEADES, Hippo pathway
Roche: ENSPRYNG, satralizumab, MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease, METEOROID
Star Therapeutics: VGA039, von Willebrand disease, VWD, Protein S, rare pediatric disease designation, Breakthrough Therapy designation
Novo Nordisk: etavopivat, pyruvate kinase-R activator, PKR activator, sickle cell disease, SCD, HIBISCUS, vaso-occlusive crisis, VOC
AstraZeneca / Alexion: Ultomiris, ravulizumab, IgA nephropathy, IgAN, I CAN, proteinuria, eGFR, complement C5
Entos Pharmaceuticals: L-CMD Research Foundation, LMNA-related congenital muscular dystrophy, L-CMD, Fusogenix PLV, non-viral delivery, gene editing